scholarly journals Work absence in patients with asthma and/or COPD: a population-based study

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Boudewijn J. H. Dierick ◽  
Bertine M. J. Flokstra-de Blok ◽  
Thys van der Molen ◽  
Núria Toledo-Pons ◽  
Miguel Román-Rodríguez ◽  
...  
Keyword(s):  
General Population ◽  
Real Life ◽  
Work Productivity ◽  
Population Based ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Work Absence ◽  
Clinical Predictors ◽  
Obstructive Pulmonary Disease ◽  
Life Study

AbstractChronic obstructive pulmonary disease (COPD) and asthma impact on work productivity, but their population-based burden and clinical predictors are understudied. In this observational, real-life study, work absence of 14,383 asthma and/or COPD patients present in the MAJORICA cohort (Spain) was compared with the general population. Using multivariable regression, we studied the association of work absence with demographic and clinical characteristics. Patients with asthma and/or COPD had more work absence than the general population (15.2% vs 8.9%, p < 0.0001). Patients with asthma had more often periods of work absence compared to patients with COPD (16.0% vs 12.8%, p < 0.0001). The number of days absent were, however, less in asthma than in COPD (median: 15 days [IQR: 5–51] vs 39 days [IQR: 13–134], p < 0.001). Patients with asthma–COPD overlap were in between (14.5% with absence; median: 27 days [IQR: 10–82]). Comorbid anxiety, allergic rhinitis, and sleep apnoea were independently associated with more work absence.

scholarly journals The Importance of Inhaler Adherence to Prevent COPD Exacerbations

2019 ◽  
Vol 7 (4) ◽  
pp. 54 ◽  
Author(s):  
Jose R Jardim ◽  
Oliver A. Nascimento
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Latin American ◽  
Real Life ◽  
Chronic Obstructive ◽  
Good Adherence ◽  
Cross Sectional ◽  
Obstructive Pulmonary Disease ◽  
Life Study ◽  
Copd Exacerbations

It has been shown that the better outcomes of chronic obstructive pulmonary disease (COPD) are closely associated with adherence to drug therapy, independent of the treatment administered. The clinical trial Towards a Revolution in COPD Health (TORCH) study clearly showed in a three year follow up that patients with good adherence to their inhaler treatment presented a longer time before the first exacerbation, a lower susceptibility to exacerbation and lower all-cause mortality. The Latin American Study of 24-hour Symptoms in Chronic Obstructive Pulmonary Disease (LASSYC), a real-life study, evaluated the self-reported inhaler adherence in COPD patients in seven countries in a cross-sectional non-interventional study and found that approximately 50% of the patients had good adherence, 30% moderate adherence and 20% poor adherence. Adherence to inhaler may be evaluated by the specific inhaler adherence questionnaire, the Test of Adherence to Inhalers (TAI). Several factors may predict the incorrect use of inhalers or adherence in COPD outpatient, including the number of devices and the daily dosing frequency. Ideally, patient education, simplicity of the device operation, the use of just one device for multiple medications and the best adaptation of the patient to the inhaler should guide the physician in prescribing the device.

scholarly journals Disability in Moderate Chronic Obstructive Pulmonary Disease: Prevalence, Burden and Assessment - Results from a Real-Life Study

Respiration ◽  
2015 ◽  
Vol 89 (2) ◽  
pp. 100-106 ◽  
Author(s):  
Fulvio Braido ◽  
Ilaria Baiardini ◽  
Nicola Scichilone ◽  
Claudio Sorino ◽  
Fabiano Di Marco ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Real Life ◽  
Disease Prevalence ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Life Study ◽  
Real Life Study ◽  
Assessment Results

scholarly journals CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis

2021 ◽  
Vol 10 (5) ◽  
pp. 936
Author(s):  
Jean-Louis Pépin ◽  
Sébastien Bailly ◽  
Pierre Rinder ◽  
Dan Adler ◽  
Daniel Szeftel ◽  
...  
Keyword(s):  
Multivariable Analysis ◽  
Real Life ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Therapy Termination ◽  
Insurance Reimbursement ◽  
Obstructive Sleep ◽  
System Data

The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French national health insurance reimbursement system data for new CPAP users aged ≥18 years were analyzed. Innovative algorithms were used to determine the presence of specific comorbidities (hypertension, diabetes and chronic obstructive pulmonary disease (COPD)). Therapy termination was defined as cessation of CPAP reimbursements. A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male). An amount of 50.7, 24.4 and 4.3% of patients, respectively, had hypertension, diabetes and COPD. Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively. On multivariable analysis, age categories, female sex (1.09 (1.08–1.10) and COPD (1.12 (1.10–1.13)) and diabetes (1.18 (1.16–1.19)) were significantly associated with higher CPAP termination risk; patients with hypertension were more likely to continue using CPAP (hazard ratio 0.96 (95% confidence interval 0.95–0.97)). Therapy termination rates were highest in younger or older patients with ≥1 comorbidity. Comorbidities have an important influence on long-term CPAP continuation in patients with OSA.

Sign in / Sign up

Export Citation Format

Share Document